Literature DB >> 33656537

Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes.

Najla El Jurdi1, Ahmad Rayes1, Margaret L MacMillan1,2,3, Shernan G Holtan1, Todd E DeFor4, Judith Witte1, Mukta Arora1, Jo-Anne Young5, Daniel J Weisdorf1.   

Abstract

Acute graft-versus-host disease (aGVHD) has various risk factors and outcomes. We defined distinct aGVHD treatment response groups based on response to first-line corticosteroids: steroid sensitive (SS), steroid resistant (SR), and the rarely studied steroid dependent (SD) aGVHD. In 1143 consecutive adult and pediatric allogeneic hematopoietic cell transplant recipients, 385 (34%) developed aGVHD, with 10% having SS aGVHD, 9% SD aGVHD, and 14% SR aGVHD. The only factor significantly associated with SD in comparison with SS was older age (odds ratio [OR], 3.9; 95% confidence interval [CI], 1.4-11.3, when comparing 18- to 60-year-olds with <18-year-olds). Factors significantly associated with SR in comparison with SS were unrelated donor (OR, 3.0; 95% CI, 1.2-7.4) and Minnesota high-risk aGVHD (OR, 2.4; 95% CI, 1.3-4.6). SR aGVHD was independently associated with higher risk for 2-year overall mortality (hazards ratio [HR], 1.8; 95% CI, 1.2-2.8) and nonrelapse mortality (NRM; HR, 2.1; 95% CI, 1.2-3.9). SS and SD GVHD groups had similar overall survival and NRM. The cumulative incidence of chronic GVHD was highest in the SD group, followed by the SR and SS groups (46%, 41%, and 29%, respectively). SD and SS GVHD had similar prognoses, both markedly better than those of the SR groups.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33656537      PMCID: PMC7948274          DOI: 10.1182/bloodadvances.2020003937

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  12 in total

1.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

2.  Non-parametric inference for cumulative incidence functions in competing risks studies.

Authors:  D Y Lin
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.

Authors:  Margaret L MacMillan; Marie Robin; Andrew C Harris; Todd E DeFor; Paul J Martin; Amin Alousi; Vincent T Ho; Javier Bolaños-Meade; James L M Ferrara; Richard Jones; Mukta Arora; Bruce R Blazar; Shernan G Holtan; David Jacobsohn; Marcelo Pasquini; Gerard Socie; Joseph H Antin; John E Levine; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-10       Impact factor: 5.742

5.  Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report.

Authors:  M Y Shapira; I B Resnick; M Bitan; A Ackerstein; P Tsirigotis; B Gesundheit; I Zilberman; S Miron; A Leubovic; S Slavin; R Or
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

6.  Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.

Authors:  Joseph Pidala; Mehdi Hamadani; Peter Dawson; Michael Martens; Amin M Alousi; Madan Jagasia; Yvonne A Efebera; Saurabh Chhabra; Iskra Pusic; Shernan G Holtan; James L M Ferrara; John E Levine; Marco Mielcarek; Claudio Anasetti; Joseph H Antin; Javier Bolaños-Meade; Alan Howard; Brent R Logan; Eric S Leifer; Theresa S Pritchard; Mary M Horowitz; Margaret L MacMillan
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

7.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.

Authors:  Margaret L MacMillan; Daniel J Weisdorf; John E Wagner; Todd E DeFor; Linda J Burns; Norma K C Ramsay; Stella M Davies; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

8.  Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial.

Authors:  I M Hings; A H Filipovich; W J Miller; B L Blazar; P B McGlave; N K Ramsay; J H Kersey; D J Weisdorf
Journal:  Transplantation       Date:  1993-09       Impact factor: 4.939

Review 9.  Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.

Authors:  Mohamad Mohty; Ernst Holler; Madan Jagasia; Robert Jenq; Florent Malard; Paul Martin; Gérard Socié; Robert Zeiser
Journal:  Blood       Date:  2020-10-22       Impact factor: 22.113

10.  EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.

Authors:  Helene M Schoemans; Stephanie J Lee; James L Ferrara; Daniel Wolff; John E Levine; Kirk R Schultz; Bronwen E Shaw; Mary E Flowers; Tapani Ruutu; Hildegard Greinix; Ernst Holler; Grzegorz Basak; Rafael F Duarte; Steven Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2018-06-05       Impact factor: 5.483

View more
  2 in total

Review 1.  Acute GVHD: think before you treat.

Authors:  Laura F Newell; Shernan G Holtan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.

Authors:  Elizabeth Stenger; Cynthia R Giver; Amelia Langston; Daniel Kota; Pankoj Kumar Das; Raghavan Chinnadurai; Jacques Galipeau; Edmund K Waller; Muna Qayed
Journal:  Front Immunol       Date:  2022-09-14       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.